• Something wrong with this record ?

Comparison of cardiocerebrovascular disease incidence between angiotensin converting enzyme inhibitor and angiotensin receptor blocker users in a real-world cohort

S. Lee, H. Kim, H. Woo Yim, K. Hun-Sung, J. Han Kim

. 2023 ; 21 (1) : 7-14. [pub] 20230327

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23002239

BACKGROUND: Both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are known to be effective in managing cardiovascular diseases, but more evidence supports the use of an ACEI. This study investigated the difference in cardiovascular disease incidence between relatively low-compliance ACEIs and high-compliance ARBs in the clinical setting. METHODS: Patients who were first prescribed ACEIs or ARBs at two tertiary university hospitals in Korea were observed in this retrospective cohort study for the incidence of heart failure, angina, acute myocardial infarction, cerebrovascular disease, ischemic heart disease, and major adverse cardiovascular events for 5 years after the first prescription. Additionally, 5-year Kaplan-Meier survival curves were used based on the presence or absence of statins. RESULTS: Overall, 2,945 and 9,189 patients were prescribed ACEIs and ARBs, respectively. When compared to ACEIs, the incidence of heart failure decreased by 52% in those taking ARBs (HR [95% CI] = 0.48 [0.39-0.60], P < 0.001), and the incidence of cerebrovascular disease increased by 62% (HR [95% CI] = 1.62 [1.26-2.07], P < 0.001). The incidence of ischemic heart disease (P = 0.223) and major adverse cardiovascular events (P = 0.374) did not differ significantly between the two groups. CONCLUSIONS: ARBs were not inferior to ACEIs in relation to reducing the incidence of cardiocerebrovascular disease in the clinical setting; however, there were slight differences for each disease. The greatest strength of real-world evidence is that it allows the follow-up of specific drug use, including drug compliance. Large-scale studies on the effects of relatively low-compliance ACEIs and high-compliance ARBs on cardiocerebrovascular disease are warranted in the future.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23002239
003      
CZ-PrNML
005      
20230530080316.0
007      
ta
008      
230406s2023 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.32725/jab.2023.002 $2 doi
035    __
$a (PubMed)37016775
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Lee, Suehyun $u Gachon University, Department of Computer Engineering, Seongnam, Republic of Korea
245    10
$a Comparison of cardiocerebrovascular disease incidence between angiotensin converting enzyme inhibitor and angiotensin receptor blocker users in a real-world cohort / $c S. Lee, H. Kim, H. Woo Yim, K. Hun-Sung, J. Han Kim
520    9_
$a BACKGROUND: Both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are known to be effective in managing cardiovascular diseases, but more evidence supports the use of an ACEI. This study investigated the difference in cardiovascular disease incidence between relatively low-compliance ACEIs and high-compliance ARBs in the clinical setting. METHODS: Patients who were first prescribed ACEIs or ARBs at two tertiary university hospitals in Korea were observed in this retrospective cohort study for the incidence of heart failure, angina, acute myocardial infarction, cerebrovascular disease, ischemic heart disease, and major adverse cardiovascular events for 5 years after the first prescription. Additionally, 5-year Kaplan-Meier survival curves were used based on the presence or absence of statins. RESULTS: Overall, 2,945 and 9,189 patients were prescribed ACEIs and ARBs, respectively. When compared to ACEIs, the incidence of heart failure decreased by 52% in those taking ARBs (HR [95% CI] = 0.48 [0.39-0.60], P < 0.001), and the incidence of cerebrovascular disease increased by 62% (HR [95% CI] = 1.62 [1.26-2.07], P < 0.001). The incidence of ischemic heart disease (P = 0.223) and major adverse cardiovascular events (P = 0.374) did not differ significantly between the two groups. CONCLUSIONS: ARBs were not inferior to ACEIs in relation to reducing the incidence of cardiocerebrovascular disease in the clinical setting; however, there were slight differences for each disease. The greatest strength of real-world evidence is that it allows the follow-up of specific drug use, including drug compliance. Large-scale studies on the effects of relatively low-compliance ACEIs and high-compliance ARBs on cardiocerebrovascular disease are warranted in the future.
650    _2
$a lidé $7 D006801
650    _2
$a inhibitory ACE $x škodlivé účinky $7 D000806
650    _2
$a antagonisté receptorů pro angiotenzin $x škodlivé účinky $7 D057911
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a incidence $7 D015994
650    12
$a infarkt myokardu $x chemicky indukované $7 D009203
650    12
$a cerebrovaskulární poruchy $x epidemiologie $x chemicky indukované $7 D002561
650    12
$a srdeční selhání $x farmakoterapie $x epidemiologie $x chemicky indukované $7 D006333
650    12
$a ischemická choroba srdeční $x epidemiologie $x chemicky indukované $7 D017202
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kim, Hyunah $u Sookmyung Women's University, College of Pharmacy, Seoul, Republic of Korea
700    1_
$a Woo Yim, Hyeon $u The Catholic University of Korea, College of Medicine, Department of Preventive Medicine, Seoul, Republic of Korea
700    1_
$a Hun-Sung, Kim $u The Catholic University of Korea, College of Medicine, Department of Medical Informatics, Seoul, Republic of Korea $u Seoul St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Seoul, Republic of Korea
700    1_
$a Han Kim, Ju $u Seoul National University College of Medicine, Systems Biomedical Informatics Research Center, Division of Biomedical Informatics, Seoul, Republic of Korea
773    0_
$w MED00012667 $t Journal of applied biomedicine $x 1214-0287 $g Roč. 21, č. 1 (2023), s. 7-14
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37016775 $y Pubmed
910    __
$a ABA008 $b B 2301 $c 1249 $y p $z 0
990    __
$a 20230406 $b ABA008
991    __
$a 20230530080312 $b ABA008
999    __
$a ok $b bmc $g 1938686 $s 1188445
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 21 $c 1 $d 7-14 $e 20230327 $i 1214-0287 $m Journal of Applied Biomedicine $n J. Appl. Biomed. (Čes. Budějovice Print) $x MED00012667
LZP    __
$b NLK198 $a Pubmed-20230406

Find record

Citation metrics

Archiving options